Skip to content
Clinical Trials – home

Benign neoplasm of ureter Trials in Disease

1 / 1 trials open to patients1 country

In short

Currently, there is one ongoing clinical trial focused on improving surgical recovery for patients with benign neoplasm of the ureter and related upper urinary tract conditions. This trial is investigating different pain management strategies to enhance recovery after robot-assisted surgery.

Clinical trial locations

Study on Spinal Morphine, Intravenous Lidocaine, and Bupivacaine for Patients Undergoing Robot-Assisted Surgery for Kidney or Ureter Conditions

This trial is being conducted in Sweden and focuses on improving recovery after robot-assisted surgery for conditions affecting the upper urinary tract. The study includes patients with benign tumors of the kidney or ureter, as well as those with related conditions such as kidney stones and kidney reflux.

Who can participate:

  • Adults scheduled for planned (non-emergency) robot-assisted surgery on the upper urinary tract
  • Patients who can provide both written and spoken consent after receiving information about the study
  • Both male and female participants are welcome

Who cannot participate:

  • Patients with cancer or malignant tumors in the kidney or ureter
  • Those with kidney stones
  • Patients with renal reflux (a condition where urine flows backward from the bladder to the kidneys)

What the trial focuses on:

The main goal of this study is to determine whether different pain management strategies can improve recovery after surgery. Researchers are comparing the effectiveness of three different approaches: spinal morphine (a strong pain reliever injected into the spinal fluid), intravenous lidocaine (a numbing medication given through a vein), and a combination of bupivacaine with adrenaline (local anesthetics that help numb the surgical area and prolong pain relief).

The trial uses a patient-centered measurement called "Quality of Recovery 15" to assess how well patients are recovering. This scale evaluates various aspects of recovery, including pain levels and overall well-being, at different time points after surgery. Participants will be randomly assigned to receive one of these treatments without knowing which one they are getting, allowing researchers to compare the results objectively.

Investigational drugs being tested:

  • Morphine: A powerful pain reliever administered into the space around the spinal cord to reduce pain and support recovery
  • Lidocaine: A local anesthetic given intravenously to help manage pain and improve postoperative recovery
  • Bupivacaine: A medication used to numb specific areas of the body, given as part of spinal pain relief to enhance recovery after surgery

The study monitors patients from the time they join the trial through 30 days after surgery, tracking pain levels, the need for additional pain medications, recovery quality, and any complications that may arise. The trial is expected to be completed by December 31, 2025.

Summary

This single ongoing trial represents an important effort to optimize surgical outcomes for patients with benign neoplasm of the ureter and related upper urinary tract conditions. Located in Sweden, the study takes a comprehensive approach to pain management during robot-assisted surgery, comparing three distinct anesthetic strategies: spinal morphine, intravenous lidocaine, and bupivacaine with adrenaline.

What makes this trial particularly valuable is its patient-centered focus on quality of recovery rather than simply measuring technical surgical success. By exploring different combinations of well-established pain medications in a new surgical context, the research aims to identify the most effective approach for helping patients recover more comfortably and quickly after this type of minimally invasive surgery.

The trial's use of robotic-assisted techniques reflects modern surgical advances, while its focus on optimizing pain management addresses one of the most important aspects of patient experience during recovery.

This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.

Clinical trials for Benign neoplasm of ureter

Recruiting trials first

See all 1 trials →
Quick filters

1 clinical trial in this condition

Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Lidocaine Hydrochloride
  • Sponsor:Region Oestergoetland
See all 1 trials →filters applied: condition = Benign neoplasm of ureter

Related conditions in the same therapeutic area

Back to all diseases
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).